Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Outlook for the Asthma Disease Market Heading Into 2029?
In recent times, the market size for asthma disease has seen significant expansion. The growth is expected to continue, increasing from $24.63 billion in 2024 to $25.93 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.3%. This progress during the historical period is linked to various factors such as the escalating incidence of asthma among city dwellers, rising levels of air pollution in industrial areas, an increased awareness regarding the symptoms and diagnosis of asthma, a surge in the use of corticosteroids and bronchodilators, and an improvement in healthcare accessibility in emerging countries.
The market size for asthma disease is anticipated to experience robust growth in the forthcoming years, with projections indicating it will surge to $31.56 billion by 2029, marking a compound annual growth rate (CAGR) of 5.0%. This expected growth is likely due to several factors, including a higher uptake of biologics for serious asthma cases, an increase in personalized medicine demand, amplified investments in asthma-related research, bolstered usage of digital health and remote patient monitoring, and a growth in telemedicine services for the management of asthma. The future trends for the predicted period involve progression in biologic therapies for severe asthma, advanced inhaler technologies integrated with smart features, the advent of AI-enabled tools for asthma monitoring, innovative strategies for personalized asthma treatment, and the creation of digital health platforms designed for the remote supervision of asthma management.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25701&type=smp
Which Factors Are Pushing The Asthma Disease Market Forward?
The increase in respiratory diseases is anticipated to drive the expansion of the asthma disease market. These respiratory diseases, which include chronic obstructive pulmonary disease (COPD), bronchitis, and asthma, are a group of illnesses that impact the lungs and breathing. The escalation of these disorders is mainly due to airway irritation and inflammation by particulate matter and nitrogen oxides, which results in breathing difficulties and exacerbation of conditions like asthma. Such diseases can elicit inflammation and airway remodeling, thus triggering or exacerbating asthma symptoms. As per the US-based National Library of Medicine, in December 2023, the projection for the year 2050 is that chronic obstructive pulmonary disease (COPD) cases in low- and middle-income nations will more than double those in higher-income nations, with sub-Saharan Africa anticipated to witness a 59% surge, making it the global leader in COPD prevalence and cases by 2040. Consequently, the escalating prevalence of respiratory ailments is augmenting the growth of the market for asthma disease.
Which Segment Held The Largest Share In The Asthma Disease Market In 2025?
The asthma disease market covered in this report is segmented –
1) By Treatment Type: Controller Medications, Rescue Medications, Biologics, Combination Therapy
2) By Cause Of Asthma: Allergic Asthma, Non-Allergic Asthma, Exercise-Induced Asthma, Occupational Asthma
3) By Severity: Mild Intermittent, Mild Persistent, Moderate Persistent, Severe Persistent
4) By Route Of Administration: Oral, Inhaled, Intravenous, Other Route Of Administration
5) By End-Users: Hospitals, Homecare, Specialty Clinics , Others End-Users
Subsegments:
1) By Controller Medications Inhaled Corticosteroids (ICS), Long-Acting Beta-Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Long-Acting Muscarinic Antagonists (LAMA), Methylxanthines
2) By Rescue Medications: Short-Acting Beta-Agonists (SABA), Systemic Corticosteroids, Anticholinergics
3) By Biologics: Anti-IGE Therapy, Anti-IL-5 Therapy, Anti-IL-4/IL-13 Therapy, Anti-TSLP Therapy
4) By Combination Therapy: ICS Or LABA Combinations, ICS Or LABA Or LAMA Combinations, ICS Or LAMA Combinations
How Are Key Trends Driving Expansion In The Asthma Disease Industry?
Leading corporations in the asthma disease market are concentrating on creating solutions like monoclonal antibody therapies to boost treatment effectiveness and patients’ results. Monoclonal antibody therapy is a specialised treatment form that utilizes lab-manufactured proteins to replicate the immune system’s capacity to counter damaging pathogens, thus providing a more exact and successful management of chronic diseases such as asthma. For example, in June 2022, the US-based medical research body, the National Institutes of Health (NIH), instituted the PANDA trial (preventing asthma in high-risk kids) to assess the monoclonal antibody dupilumab as a therapy for urban youth suffering from asthma. The PANDA trial, a Phase 2, randomized, placebo-controlled study aims to test dupilumab in about 240 children ranging from ages 6-17 years with poorly controlled, type 2 inflammation, severe allergic asthma residing in low-income urban regions. Participants get subcutaneous injections bi-weekly for a year along with standard asthma care, and are randomized in a 2:1 ratio to receive dupilumab or a placebo. The trial also features mechanistic investigations utilizing nasal swabs and blood samples to study gene expression, primarily during respiratory viral infections, with a goal to comprehend the molecular pathways of asthma flare-ups and treatment responsiveness in this high-risk pediatric group.
Which Organizations Are Driving Progress In The Asthma Disease Industry?
Major companies operating in the asthma disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chiesi Farmaceutici S.p.A., Cipla Limited, Mundipharma International Limited, Generate Biomedicines.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/asthma-disease-global-market-report
Which Region Is Expected To Experience The Highest Growth In The Asthma Disease Industry?
North America was the largest region in the asthma disease market in 2024. The regions covered in the asthma disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=25701&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model